Clearpoint Neuro Inc. (CLPT) PT Raised to $30 at Lake Street Capital Markets

Lake Street Capital Markets analyst Frank Takkinen raised the price target on Clearpoint Neuro Inc. (NASDAQ: CLPT) to $30.00 (from $17.00) while maintaining a Buy rating.

The analyst commented: "The core business is humming, and the step-function potential of the partner business has had key de-risking developments that reduce time to market. While shares have had a meaningful move, we still do not think investors fully appreciate the potential of the partner business. We think the proper way to value shares is on $37M of “core revenue” (LSCM 2025E) plus $100M of new drug/device revenue. Importantly, just one of the 50 partner products (7 fast-tracked) needs to be successful to achieve over $100M of combo therapy revenue with 70%+ GMs and limited incremental opex. Over time, we expect a basket of approved combo-therapies will be on the market, providing multiple growth opportunities for ClearPoint. We reiterate our Buy and increase PT to $30."

You May Also Be Interested In

• Tesla readies August launch of CyberCab - The Information
• York Space Systems (YSS) PT Lowered to $15 at Jefferies
• BofA Securities Starts Definium Therapeutics Inc (DFTX) at Buy